ArticleAIDS care2021
Polypharmacy and frailty among persons with HIV.
Article in AIDS care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Plasma NfL and sCD14 Are Associated with Polypharmacy and Recurrent Falls in Virally Suppressed Older People with HIV.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Introducing the WHO ICOPE approach into HIV care: A perspective on healthy ageing in people living with HIV.JAR life · 2026Article
- Influence of antiretroviral therapy on frailty among people living with HIV.Scientific reports · 2025Observational
- Approaches to optimally target frailty screening among people with HIV in clinical care: findings from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Alcohol Use and Its Associations With Frailty, Fractures, and Falls Among Older Adults With HIV.Alcohol research : current reviews · 2025Review
- Prevalence of medication overload among older people with HIV: a MedSafer study.BMC infectious diseases · 2024Article
- Integrating frailty interventions into existing care models: a comprehensive approach to enhancing patient outcomes in chronic disease management.Frontiers in public health · 2024Review
- Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic.Drugs & aging · 2023Article
- Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment.Drug and alcohol dependence · 2022Article
- Alcohol use, physical activity, and muscle strength moderate the relationship between body composition and frailty risk among people living with HIV.Alcoholism, clinical and experimental research · 2022Article
- [Cost and factors associated with the prescription of non-antiretroviral drugs among HIV-infected patients under antiretroviral therapy in a reference hospital in Morocco].Medecine tropicale et sante internationale · 2022Article
- Frailty and HIV: Moving from Characterization to Intervention.Current HIV/AIDS reports · 2021Review
- Conceptualizing and treating the polytrauma clinical triad as a complex chronic pain syndrome.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polypharmacy is associated with frailty in the general population, but little is known about polypharmacy among persons living with HIV (PLWH) on antiretroviral (ARV) therapy. We determined the association between polypharmacy and an adapted frailty-related phenotype (aFRP) via a cross-sectional study in FY 2009 of 1762 PLWH on ARV with suppressed viral load and 2679 uninfected participants in the Veterans Aging Cohort Study. The primary predictor was number of chronic outpatient non-ARV medications using pharmacy fill/refill data. The outcome was self-report of four aFRP domains: shrinking, exhaustion, slowness, low physical activity. Frailty was defined as reporting 3-4 domains while pre-frailty was 1-2. Frailty was uncommon (2% PLWH, 3% uninfected); a larger proportion demonstrated any aFRP domain (31% PLWH, 41% uninfected). Among PLWH and uninfected, median chronic non-ARV medications was 6 and 16 respectively if having any aFRP domain, and 4 and 10 when without aFRP domains. In adjusted analyses, each additional chronic non-ARV medication conferred an 11% increased odds of having any aFRP domain in PLWH (OR [95% CI] = 1.11 [1.08, 1.14]), and a 4% increase in those uninfected (OR [95% CI] = 1.04 [1.03, 1.04]). The stronger association between polypharmacy and frailty in PLWH warrants further study and potential deprescribing of medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.